News

The companies say that this is the first prescription osteoporosis therapy to include calcium. The new treatment option comes in light of a recent Surgeon General’s Report on

The FDA has informed the company in a preliminary communication that it still requires further information before it will grant its approval for the drug. The company has

According to the company one of these compounds has already shown repeated efficacy in blocking tumors in a pre-clinical model of breast cancer. Other compounds in the family

The company is currently in discussions with the Food and Drug Administration in order to finalize the details of this trial. The FDA has made recommendations regarding secondary

Prior to this approval the drug was only approved for use in people two years of age and older. The younger age indication for Vaqta was supported by

The market for preserving cells and tissue is growing rapidly and is diverging into new technology areas, one of which is vitrification, or freezing rapidly to avoid the

The grant was awarded under the foundation’s drug discovery and development program aimed at addressing obstacles that currently impede progress in bringing new Parkinson’s disease therapies to market.

This approval triggers the final milestone payment of $4 million to Upsher-Smith Laboratories under Unigene’s exclusive US licensing agreement. Fortical will be manufactured at Unigene’s production facility in

As part of the agreement, Labopharm could receive payments of up to $170 million, including an up-front licensing fee of $20 million, a payment of up to $40